Stefan Baumeister

Dr. Stefan Baumeister

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2017 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
CBChristian Baarlink
Christian Baarlink
MPMatthias Plessner
Matthias Plessner
ASAlice Sherrard
Alice Sherrard
KMKohtaro Morita
Kohtaro Morita
SMShinji Misu
Shinji Misu
RGRobert Grosse
Robert Grosse

1 May 2013 in Genes & Development
Verified
Journal Article
Closed access
PDF file
SBSilvia Bicker
Silvia Bicker
SKSharof Khudayberdiev
Sharof Khudayberdiev
KWKerstin Weiß
Kerstin Weiß
KZKathleen Zocher
Kathleen Zocher
Stefan BaumeisterStefan Baumeister
Stefan Baumeister
GSGerhard Schratt
Gerhard Schratt
Specific microRNAs (miRNAs), including miR-134, localize to neuronal dendrites, where they control synaptic protein synthesis and plasticity. However, the mechanism of miRNA transport is unknown. We found that the neuronal precursor-miRNA-134 (pre-miR-134) accumulates in dendrites of hippocampal neurons and at synapses in vivo. Dendritic localization of pre-miR-134 is mediated by the DEAH-box helicase DHX36, which directly associates with the pre-miR-134 terminal loop. DHX36 function is required for miR-134-dependent inhibition of target gene expression and the control of dendritic spine size. Dendritically localized pre-miR-134 could provide a local source of miR-134 that can be mobilized in an activity-dependent manner during plasticity.

10 January 2011 in Journal of Proteome Research
Verified
Journal Article
Closed access
WRWencke Reiher
Wencke Reiher
CSChristine Shirras
Christine Shirras
JKJörg Kahnt
Jörg Kahnt
Stefan BaumeisterStefan Baumeister
Stefan Baumeister
RIR. Elwyn Isaac
R. Elwyn Isaac
Christian WegenerChristian Wegener
Christian Wegener

1 April 2007 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
ASAhmad Saleh
Ahmad Saleh
JFJohannes Friesen
Johannes Friesen
Stefan BaumeisterStefan Baumeister
Stefan Baumeister
UGUwe Gross
Uwe Gross
WBWolfgang Bohne
Wolfgang Bohne
Both apicomplexan parasites Toxoplasma gondii and Plasmodium falciparum lack type I NADH dehydrogenases (complex I) but instead carry alternative (type II) NADH dehydrogenases, which are absent in mammalian cells and are thus considered promising antimicrobial drug targets. The quinolone-like compound 1-hydroxy-2-dodecyl-4(1H)quinolone (HDQ) was recently described as a high-affinity inhibitor of fungal alternative NADH dehydrogenases in enzymatic assays, probably by interfering with the ubiquinol binding site of the enzyme. We describe here that HDQ effectively inhibits the replication rates of P. falciparum and T. gondii in tissue culture. The 50% inhibitory concentration (IC50) of HDQ for T. gondii was determined to be 2.4+/-0.3 nM with a growth assay based on vacuole sizes and 3.7+/-1.4 nM with a growth assay based on beta-galactosidase activity. Quantification of the P. falciparum replication rate using a fluorometric assay revealed an IC50 of 14.0+/-1.9 nM. An important feature of the HDQ structure is the length of the alkyl side chain at position 2. Derivatives with alkyl side chains of C6, C8, C12 (HDQ), and C14 all displayed excellent anti-T. gondii activity, while a C5 derivative completely failed to inhibit parasite replication. A combined treatment of T. gondii-infected cells with HDQ and the antimalarial agent atovaquone, which blocks the ubiquinol oxidation site of cytochrome b in complex III, resulted in synergism, with a calculated fractional inhibitory concentration of 0.16 nM. Interference of the mitochondrial ubiquinone/ubiquinol cycle at two different locations thus appears to be a highly effective strategy for inhibiting parasite replication. HDQ and its derivatives, particularly in combination with atovaquone, represent promising compounds with a high potential for antimalarial and antitoxoplasmal therapy.

4 May 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Stefan BaumeisterStefan Baumeister
Stefan Baumeister
JWJochen Wiesner
Jochen Wiesner
ARArmin Reichenberg
Armin Reichenberg
MHMartin Hintz
Martin Hintz
SBSven Bietz
Sven Bietz
FSFrank Seeber
Frank Seeber
Highly charged compounds typically suffer from low membrane permeability and thus are generally regarded as sub-optimal drug candidates. Nonetheless, the highly charged drug fosmidomycin and its more active methyl-derivative FR900098 have proven parasiticidal activity against erythrocytic stages of the malaria parasite Plasmodium falciparum. Both compounds target the isoprenoid biosynthesis pathway present in bacteria and plastid-bearing organisms, like apicomplexan parasites. Surprisingly, the compounds are inactive against a range of apicomplexans replicating in nucleated cells, including Toxoplasma gondii. Since non-infected erythrocytes are impermeable for FR90098, we hypothesized that these drugs are taken up only by erythrocytes infected with Plasmodium. We provide evidence that radiolabeled FR900098 accumulates in theses cells as a consequence of parasite-induced new properties of the host cell, which coincide with an increased permeability of the erythrocyte membrane. Babesia divergens, a related parasite that also infects human erythrocytes and is also known to induce an increase in membrane permeability, displays a similar susceptibility and uptake behavior with regard to the drug. In contrast, Toxoplasma gondii-infected cells do apparently not take up the compounds, and the drugs are inactive against the liver stages of Plasmodium berghei, a mouse malaria parasite. Our findings provide an explanation for the observed differences in activity of fosmidomycin and FR900098 against different Apicomplexa. These results have important implications for future screens aimed at finding new and safe molecular entities active against P. falciparum and related parasites. Our data provide further evidence that parasite-induced new permeability pathways may be exploited as routes for drug delivery.

27 August 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
PSPhilipp Schneider
Philipp Schneider
JBJuan Miguel Bayo-Fina
Juan Miguel Bayo-Fina
RSRajeev Singh
Rajeev Singh
PDPavan Kumar Dhanyamraju
Pavan Kumar Dhanyamraju
PHPhilipp Holz
Philipp Holz
MLMatthias Lauth
Matthias Lauth
The Down syndrome-associated DYRK1A kinase has been reported as a stimulator of the developmentally important Hedgehog (Hh) pathway, but cells from Down syndrome patients paradoxically display reduced Hh signalling activity. Here we find that DYRK1A stimulates GLI transcription factor activity through phosphorylation of general nuclear localization clusters. In contrast, in vivo and in vitro experiments reveal that DYRK1A kinase can also function as an inhibitor of endogenous Hh signalling by negatively regulating ABLIM proteins, the actin cytoskeleton and the transcriptional co-activator MKL1 (MAL). As a final effector of the DYRK1A-ABLIM-actin-MKL1 sequence, we identify the MKL1 interactor Jumonji domain demethylase 1A (JMJD1A) as a novel Hh pathway component stabilizing the GLI1 protein in a demethylase-independent manner. Furthermore, a Jumonji-specific small-molecule antagonist represents a novel and powerful inhibitor of Hh signal transduction by inducing GLI1 protein degradation in vitro and in vivo.